Policy

Celairis Therapeutics has secured exclusive rights to commercialise Ocugen's investigational gene therapy for retinitis pigmentosa in Australia, New Zealand and the member states of the Association of Southeast Asian Nations.

The Therapeutic Goods Administration has completed its inspection of Q-Gen Cell Therapeutics, the Brisbane contract manufacturer that will make Miro Sciences' StemSmart stem cell product for a planned Phase 2 trial in refractory Crohn's disease.

Syntara has paused recruitment in its Phase 1b study of SNT-9465 after some participants reported mild to moderate skin irritation from the topical scar treatment.

Immutep has released the first survival data from EFTISARC NEO, a Phase II trial of its immunotherapy eftilagimod alfa in patients with soft tissue sarcoma that can be surgically removed. The results will be presented at the Connective Tissue Oncology Society annual meeting in Seoul later this month.

Brandon Capital is inviting biotechnology, healthcare and life sciences businesses to take up office space alongside it at 31 Queen Street in the Melbourne CBD, where the venture investor has its Melbourne base on Level 9.

Melbourne biotechnology company Cartherics will use London Life Sciences Week to seek international partners, collaborators, and investors as its lead ovarian cancer therapy moves toward its first human trial.

NuNerve is taking its lead motor neurone disease therapy into a national Phase 2 trial after early signs of disease stabilisation and functional improvement in its first human study.

Tetratherix has reworked its royalty arrangements with the University of Sydney, replacing a layered set of payment obligations with a single flat royalty that the company says will strengthen its margins as its first products approach market.

Nexsen says it aims to file its RenalSure bedside test for acute kidney injury with the US Food and Drug Administration in mid-2027. It has also started a feasibility study with Austrian company GENSPEED Biotech to evaluate a second, complementary test for the condition.

CLINUVEL managing director Philippe Wolgen has rejected calls from some shareholders for a share buyback. At the company's annual general meeting in Melbourne, he said the board would keep investing cash in research and a planned business transformation.

AVITA Medical has raised its full-year revenue guidance and removed the going concern qualification from its accounts after a third quarter in which revenue grew 53 per cent on the same period last year.

Miro Sciences, formerly NeuroScientific Biopharmaceuticals, has announced that it plans to start a randomised Phase 2 trial of its StemSmart cell therapy for people with severe Crohn's disease who have failed existing treatments.